Copied
 
 
2023, DKK
04.07.2024
Bruttoresultat

501''

Primær drift

352''

Årets resultat

244''

Aktiver

3.624''

Kortfristede aktiver

1.199''

Egenkapital

307''

Afkastningsgrad

10 %

Soliditetsgrad

8 %

Likviditetsgrad

55 %

Resultat
04.07.2024
Årsrapport
2023
04.07.2024
2022
29.06.2023
2021
27.06.2022
2020
14.06.2021
2019
29.05.2020
2018
31.05.2019
2017
06.06.2018
2016
09.06.2017
2015
08.06.2016
Nettoomsætning2.092.565.0002.517.996.0002.185.033.0001.455.071.000996.136.000692.613.000643.563.000521.795.000320.466.000
Bruttoresultat501.294.000936.958.000831.905.000451.971.000257.109.000162.263.000156.786.00000
Resultat af primær drift352.214.000793.463.000733.044.000370.499.000203.455.000119.338.000102.760.00068.417.00022.308.000
Indtægter af kapitalandele (tilknyttede og associerede) 000000000
Finansielle indtægter5.581.00022.0008.636.0000234.0004.613.000865.0001.371.0003.292.000
Finansieringsomkostninger-41.761.000-25.015.0000-13.375.000-5.570.000-342.000-7.903.000-15.192.000-17.228.000
Andre finansielle omkostninger00-7.622.000000000
Resultat før skat316.034.000768.469.000734.058.000357.124.000198.119.000123.609.00095.722.00054.596.0008.373.000
Resultat243.869.000598.949.000571.735.000278.538.000154.328.00096.167.00074.528.00068.222.0008.373.000
Forslag til udbytte0-598.000.000-571.000.000-278.000.000-154.000.000-96.000.000000
Aktiver
04.07.2024
Årsrapport
2023
04.07.2024
2022
29.06.2023
2021
27.06.2022
2020
14.06.2021
2019
29.05.2020
2018
31.05.2019
2017
06.06.2018
2016
09.06.2017
2015
08.06.2016
Kortfristede varebeholdninger480.147.000493.498.000419.001.000210.790.000125.279.00036.728.00038.477.00042.763.00027.174.000
Kortfristede tilgodehavender fra salg og tjenesteydelser 709.387.000738.595.0001.216.546.000563.944.000323.564.000212.861.000195.661.000263.393.000158.637.000
Likvider9.189.000219.395.000476.897.000836.355.000176.082.00086.685.00038.592.00048.315.00023.228.000
Kortfristede aktiver1.198.723.0001.451.488.0002.112.445.0001.611.089.000624.925.000336.274.000272.730.000354.472.000209.041.000
Immaterielle aktiver og goodwill15.237.00020.033.00022.620.00026.342.00029.547.00032.568.00038.478.00044.389.00046.692.000
Finansielle anlægsaktiver23.609.00022.765.00020.367.00017.126.00016.047.00015.350.00016.557.00015.701.00015.433.000
Materielle aktiver2.386.107.0001.945.140.000985.231.000692.984.000511.911.000250.393.000173.809.000166.422.000133.063.000
Langfristede aktiver2.424.953.0001.987.938.0001.028.218.000736.452.000557.505.000298.311.000228.844.000226.511.000195.188.000
Aktiver3.623.676.0003.439.426.0003.140.663.0002.347.541.0001.182.430.000634.585.000501.574.000580.983.000404.229.000
Aktiver
04.07.2024
Passiver
04.07.2024
Årsrapport
2023
04.07.2024
2022
29.06.2023
2021
27.06.2022
2020
14.06.2021
2019
29.05.2020
2018
31.05.2019
2017
06.06.2018
2016
09.06.2017
2015
08.06.2016
Forslag til udbytte0598.000.000571.000.000278.000.000154.000.00096.000.000000
Egenkapital307.426.000661.277.000633.585.000339.677.000215.139.000316.811.000290.644.000216.116.000147.895.000
Hensatte forpligtelser19.276.00021.125.00019.111.00018.840.0009.343.0000000
Langfristet gæld til banker000000000
Anden langfristet gæld20.843.00032.725.00010.615.0000000
Leverandører af varer og tjenesteydelser207.649.000180.305.000146.619.00093.005.00093.330.00031.292.00031.326.00036.722.00031.508.000
Kortfristede forpligtelser2.180.601.0001.939.308.0001.882.633.0001.332.860.000708.893.000279.909.000181.632.000332.595.000101.208.000
Gældsforpligtelser3.316.250.0002.778.149.0002.507.078.0002.007.864.000967.291.000317.774.000210.930.000364.867.000256.334.000
Forpligtelser3.316.250.0002.778.149.0002.507.078.0002.007.864.000967.291.000317.774.000210.930.000364.867.000256.334.000
Passiver3.623.676.0003.439.426.0003.140.663.0002.347.541.0001.182.430.000634.585.000501.574.000580.983.000404.229.000
Passiver
04.07.2024
Nøgletal
04.07.2024
Årsrapport
2023
04.07.2024
2022
29.06.2023
2021
27.06.2022
2020
14.06.2021
2019
29.05.2020
2018
31.05.2019
2017
06.06.2018
2016
09.06.2017
2015
08.06.2016
Afkastningsgrad 9,7 %23,1 %23,3 %15,8 %17,2 %18,8 %20,5 %11,8 %5,5 %
Dækningsgrad 24,0 %37,2 %38,1 %31,1 %25,8 %23,4 %24,4 %Na.Na.
Resultatgrad 11,7 %23,8 %26,2 %19,1 %15,5 %13,9 %11,6 %13,1 %2,6 %
Varelagerets omsætningshastighed 4,4 5,1 5,2 6,9 8,0 18,9 16,7 12,2 11,8
Egenkapitals-forretning 79,3 %90,6 %90,2 %82,0 %71,7 %30,4 %25,6 %31,6 %5,7 %
Payout-ratio Na.99,8 %99,9 %99,8 %99,8 %99,8 %Na.Na.Na.
Gældsdæknings-nøgletal 843,4 %3.171,9 %Na.2.770,1 %3.652,7 %34.894,2 %1.300,3 %450,3 %129,5 %
Soliditestgrad 8,5 %19,2 %20,2 %14,5 %18,2 %49,9 %57,9 %37,2 %36,6 %
Likviditetsgrad 55,0 %74,8 %112,2 %120,9 %88,2 %120,1 %150,2 %106,6 %206,5 %
Resultat
04.07.2024
Gæld
04.07.2024
Årsrapport
04.07.2024
Nyeste:01.01.2023- 31.12.2023(offentliggjort: 04.07.2024)
Beretning
04.07.2024
Dato for ledelsens godkendelse af årsrapporten:2024-06-28
Ledelsespåtegning:Statement by the Management on the Annual ReportToday the Board of Directors and the Executive Board presented the Annual Report for 2023 of AGC Biologics A/S. The Annual Report has been presented in accordance with the Danish Financial Statements Act. In our opinion, the Financial Statements provide a true and fair view of the Company’s assets, liabilities, equity and cash flow, financial position at 31 December 2023 and results of the Company’s activities in the accounting period 1 January - 31 December 2023. In our opinion, the Management’s Review provides a fair review of the matters the review deals with. We recommend that the Annual Report be approved at the Annual General Meeting.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Activities and Business ModelAGC Biologics A/S (“AGC” or the “Company”) is a Contract Development Manufacturing Organization (CDMO) that provides high value added process and analytical development, scale-up and production of biological drug substances such as antibodies to the biopharmaceutical industry. The Company has a comprehensive service offering and is capable of taking a product from the early stage to commercial production. The service palette gøs from cell line and process development over analytical testing and formulation development to both clinical and commercial manufacturing. All supported by quality services, including regulatory support. The Company is owned by AGC Inc. and is a part of the AGC Biologics Group. AGC Biologics Group has fully integrated process development and manufacturing operations in Copenhagen, Denmark (AGC Biologics A/S), Seattle, Boulder and Longmont, USA (AGC Biologics Inc. ), Heidelberg, Germany (AGC Biologics GmbH) and Chiba, Japan (AGC Inc. ). The AGC Biologics Group also has cell & gene therapy facilities in Milan, Itality (AGC Biologics S. p.A. ) and in Longmont, Colorado (AGC Biologics Inc. ). AGC Biologics A/S is conducting all its activities out of the Danish facility. 2023 was a year characterized by challenging market conditions due to the global economical and political situation, that together with a significant reduction in our supplies to the COVID-19 vaccine programs, impacted both revenue and profit negatively. Several late stage clinical programs continued drug substance manufacturing at AGC in 2023. The Company will continue supply drug substance for final clinical registration trials and also supply drug substance for long-term commercial launch. In order to accommodate the expected strong business intake going forward AGC has continued to strengthen its infrastructure and increased its workforce. In 2023, the construction of a new mammalian production facility next to the existing production facility continued. The DKK 1. 5 billion investment will more than double the current mammalian production capacity when completed in June 2024. Further, in 2023 AGC continued to emphasize safety, compliance, quality, customer satisfaction, increased market reach, timely and reliable delivery, highest quality standards and “best-in-class” technology. Since AGC was started in 2001, the Company’s growth is a result of significant repeat business from customers, combined with an enlarged customer base and an important increase in the average customer contract size. This positive development has to a very large extent been possible due to the highly skilled and dedicated employees at AGC. As the number of customers and projects increases and contracts become larger, higher demands are imposed on the Company's ability to manage a complex and increasingly differentiated production portfolio. To ensure flexibility, high quality, robustness and efficient production AGC continued also in 2023 to strengthen its organization and production processes.
Vi bruger cookies til at øge oplevelsen og målrette vores markedsføring.
Ved at klikke OK tillader du brug af cookies. Læs mere her.
OK